Applovin Corporation vs Moderna, Inc. — how do they compare? Applovin Corporation trades at $314.51 (market cap $106.65B), while Moderna, Inc. trades at $61.4 (market cap $24.18B). The key difference: Applovin Corporation is far larger — about 4.4× Moderna, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.
| APP | MRNA | |
|---|---|---|
Market Cap | $106.65B | $24.18B |
Sector | Technology | Health |
52-Week High | $733.60 | $81.80 |
52-Week Low | $318.68 | $22.36 |
Enterprise Value | $107.11B | $20.33B |
Signals from Pluang's Aura AI — not financial advice
AppLovin (APP) trades at $313.50, down 7.52% in the last 24 hours, reflecting recent volatility after a Q2 2026 revenue miss. The stock is technically bearish with key support at $306, while fundamentals remain strong with 53% YoY revenue growth, 64.58% net income margin, and robust cash flow. Recent news highlights a Bank of America downgrade to Neutral, citing uncertainty around sustaining 30% long-term revenue growth, contributing to negative sentiment despite strong profitability.
The outlook is mixed: strong fundamentals and an 80.77% analyst buy rating with a $556.53 consensus price target suggest significant upside, but execution risks and growth sustainability concerns pose near-term headwinds. Investors face a trade-off between attractive valuation multiples and potential volatility from competitive and operational challenges in the ad-tech sector.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Latest headlines on both assets
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →